Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 N676K |
| Therapy | Midostaurin |
| Indication/Tumor Type | hematologic cancer |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 N676K | hematologic cancer | decreased response | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FLT3 N676K were less sensitive to Rydapt (midostaurin) compared to cells expressing a FLT3-ITD in culture (PMID: 40196870). | 40196870 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40196870) | Anti-Tumor Effects of Gilteritinib on FLT3 Mutations: Insights into Resistance Mechanisms in Ba/F3 Cell Models. | Full reference... |